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The orphan nuclear hormone receptor SHP interacts with a number of other nuclear hormone receptors and
inhibits their transcriptional activity. Several mechanisms have been suggested to account for this inhibition.
Here we show that SHP inhibits transactivation by the orphan receptor hepatocyte nuclear factor 4 (HNF-4)
and the retinoid X receptor (RXR) by at least two mechanisms. SHP interacts with the same HNF-4 surface
recognized by transcriptional coactivators and competes with them for binding in vivo. The minimal SHP
sequences previously found to be required for interaction with other receptors are sufficient for interaction with
HNF-4, although deletion results indicate that additional C-terminal sequences are necessary for full binding
and coactivator competition. These additional sequences include those associated with direct transcriptional
repressor activity of SHP. SHP also competes with coactivators for binding to ligand-activated RXR, and based
on the ligand-dependent interaction with other nuclear receptors, it is likely that coactivator competition is a
general feature of SHP-mediated repression. The minimal receptor interaction domain of SHP is sufficient for
full interaction with RXR, as previously described. This domain is also sufficient for full coactivator compe-
tition. Functionally, however, full inhibition of RXR transactivation requires the presence of the C-terminal
repressor domain, with only weak inhibition associated with this receptor interaction domain. Overall, these
results suggest that SHP represses nuclear hormone receptor-mediated transactivation via two separate steps:
first by competition with coactivators and then by direct effects of its transcriptional repressor function.
Nuclear hormone receptors are transcription factors whose
activities are regulated by direct binding of small lipophilic
molecules such as steroids, thyroid hormone, retinoids, and
vitamin D3 (24). These receptors have been studied extensively
due to their important roles in the control of development and
cellular homeostasis. The nuclear hormone receptor superfam-
ily also includes numerous orphan receptors, which do not
have identified ligands (10, 23). The structural similarities
shared by superfamily members reside in two distinct func-
tional domains. The first and most highly conserved is the
DNA binding domain, also called the C domain, which targets
receptors to specific DNA sequences known as hormone re-
sponse elements. The second is the ligand binding domain
(LBD), which is also called the E domain. It is located in the
C-terminal region and is involved in several functions in addi-
tion to ligand binding, including dimerization and ligand-de-
pendent transcriptional activation.
Crystallographic studies (e.g., references 30, 43, and 46)
have revealed that ligand binding provokes a conformational
change in the receptors that allows them to bind a diverse
group of proteins termed coactivators (reviewed in references
14, 37, and 47). These coactivators bind to a common surface
of the receptors formed by several alpha-helices (8, 27, 36),
and it is thought that the appropriate positioning of the C-
terminal helix 12 in response to ligand binding is of particular
importance in promoting coactivator interaction. The ligand-
dependent transcriptional activation function is referred to as
AF-2, and a conserved sequence within helix 12 (7) that is
required for coactivator binding is referred to as the AF-2
motif.
One important group of related coactivators is encoded by
three genes, each of which has multiple names (37, 47). The
first described was SRC-1 (27), which was followed by SRC-2,
which is also known as TIF2 (39) or GRIP-1 (12), and by
SRC-3, which is also known as ACTR (5), AIB1 (1), p/CIP
(38), RAC3 (20), and TRAM-1 (40). These proteins, which are
all approximately 160 kDa, show strong ligand-dependent in-
teraction with the AF-2 surface of the receptors and are able to
stimulate receptor transactivation when overexpressed. An-
other group of two related proteins, CBP and p300, also stim-
ulate ligand-dependent transactivation by the receptors (e.g.,
reference 18). These two proteins, which can interact with
members of the p160/SRC family, also function as coactivators
for many other transcription factors (47). Finally, there are a
number of other potentially important coactivators that also
stimulate nuclear hormone-mediated transactivation and show
either AF-2-dependent (e.g., reference 26) or AF-2-indepen-
dent (e.g., reference 5) interaction with receptors.
At least two general mechanisms are thought to account for
the effects of the coactivators. Several lines of evidence indi-
cate that they can counteract inhibitory chromatin effects. At
least for SRC-1 (39), ACTR/SRC-3 (6), p300/CBP (3, 28), and
p/CAF (49), this is thought to be a consequence of their in-
trinsic histone acetyltransferase activity. It is also thought that
these coactivators may function more directly to recruit RNA
polymerase to promoters by interactions with components of
the basal transcriptional apparatus (4).
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Among the numerous proteins initially identified on the
basis of interaction with receptor LBDs is an unusual orphan
nuclear receptor, SHP. This orphan was originally isolated on
the basis of its interaction with the new receptor CAR, using
the Saccharomyces cerevisiae two-hybrid assay (32). Initial stud-
ies demonstrated that SHP lacks a DNA binding domain and
that it exhibits functional interactions with several other nu-
clear hormone receptors in addition to CAR (32). In general,
SHP acts to decrease transactivation by its partners in tran-
sient-transfection assays. This inhibitory effect was first attrib-
uted to an inhibition of DNA binding of the SHP targets.
However, further studies revealed that SHP itself carries a
novel autonomous repression domain in its C-terminal region
(33). The existence of this domain suggested that SHP could
also act to inhibit transcription if it could interact with DNA-
bound receptor targets. Support for this alternative possibility
was recently provided by results demonstrating that SHP is an
effective inhibitor of estrogen receptor (ER) transactivation,
even though it does not block binding of ER to estrogen
response elements (34).
The inhibitory effect of SHP on ER raises two important
questions. Because ER is in the group of receptors thought to
function exclusively as homodimers, the first question is
whether the range of SHP targets could include other super-
family members in this group. Of these superfamily members,
the orphan HNF-4 is particularly interesting, since loss of func-
tion of a single HNF-4 allele causes the syndrome of mature-
onset diabetes of the young (48). HNF-4 is expressed in liver
and in the insulin-producing pancreatic beta cells, and the
potential importance of any functional interaction between
SHP and HNF-4 was recently extended by preliminary results
indicating that SHP is expressed not only in liver, as previously
described (32), but also in beta cells. The second question
concerns the mechanism of the inhibitory effects of SHP on
DNA-bound targets. In addition to the inherent SHP repressor
function, a recent report has suggested yet another mechanism
for repression, in which SHP interferes with coactivator bind-
ing to ER (17). The relative contributions of the direct repres-
sor activity and the indirect interference with coactivator func-
tion to SHP-mediated inhibition of ER and other targets
remain unclear.
We have examined both the potential interaction of SHP
with HNF-4 and the molecular basis for its inhibitory effects.
As with other superfamily members, SHP is an effective inhib-
itor of HNF-4 transactivation. SHP requires the conserved
AF-2 motif for interaction with HNF-4 and also with retinoid
X receptor (RXR) and can compete with coactivators for bind-
ing to both. At least in the case of RXR inhibition, loss of the
SHP repressor function strongly weakens but does not com-
pletely block SHP-mediated repression. This supports the
functional importance of this domain and suggests a two-step
model for SHP inhibition. In this model, an initial inhibitory
effect results from the loss of coactivator binding due to com-
petition by SHP. Full inhibition depends on the second step, in
which the SHP repressor domain acts directly to further de-
crease expression.
MATERIALS AND METHODS
Plasmids. All of the HNF-4-related constructs, including mammalian expres-
sion vectors for wild-type HNF-4 and mutants, Gal4-HNF4 chimeras, and the
reporter construct (BA1)5CAT were described previously (12). VP16-HNF4 was
constructed by insertion of a PCR-amplified fragment containing the LBD of
HNF-4 into the previously described mammalian VP16 fusion vector (11). Gal4
fusions of full-length and deletion mutants of murine SHP, CDM8SHP, and the
Gal4Tkluc reporter construct were also described elsewhere (33). pCMX-SRC3
was a kind gift from J. D. Chen (University of Massachusetts, Worcester).
Gal4SRC-3(RID) was constructed by insertion of PCR-amplified receptor in-
teraction domain of SRC-3 (amino acids 601 to 761) into pCMXVP16.
VP16RXRD19C was generated by insertion of human RXRa sequence from
CDMhRXRD19C (51) into the previously described pCMXVP16 vector (11).
For in vitro translation, HNF-4 inserts were reintroduced into pCMXGal4 plas-
mid. pT7lac-hRXRa and CDMhRXRD19C have been described previously (51).
Transient-transfection assays. Plasmids were transfected into 50 to 60% con-
fluent HepG2 cells by the calcium phosphate DNA coprecipitation method, as
described previously (9, 20). For luciferase assays, cells were maintained in
24-well plates. For chloramphenicol acetyltransferase (CAT) assays, cell were
maintained in 30-mm-diameter dishes. CAT, luciferase, and growth hormone
(GH) activities were assayed approximately 48 h after addition of calcium phos-
phate DNA precipitates. For ligand treatment, cells were transfected in medium
containing 10% charcoal-stripped fetal bovine serum and treated with the ligands
for approximately 30 h. 9-cis-retinoic acid (9-cis-RA) was purchased from Biomol
(Plymouth Meeting, Pa.) and LG1069 was from Glaxo Wellcome (Research Park
Triangle, N.C.). For CAT assays, cells were collected in TEN solution (0.04 M
Tris-HCl [pH 7.4], 1 mM EDTA, 0.15 M NaCl), and whole-cell extracts were
prepared in 0.25 M Tris-HCl, pH 7.8, by three sequential freeze-thaw cycles.
CAT activities were determined by using [14C]chloramphenicol and acetyl coen-
zyme A as previously described. Nonacetylated and acetylated chloramphenicol
forms were separated on IB2 silica gel plates by using chloroform-methanol
(95:5) for development, and radioactive spots, detected by autoradiography,
were cut from the thin-layer plates and counted. CAT enzyme levels that exhib-
ited more than 60% conversion of acetylated product were diluted and reassayed
for CAT activity in the linear range.
In vitro binding assays. In vitro binding assays were performed with glutathi-
one S-transferase (GST) and GST fusion proteins expressed in Escherichia coli
and bound to glutathione agarose, and appropriate [35S]methionine-labeled tar-
get proteins were produced by in vitro translation. Incubation and removal of
nonspecifically bound proteins were performed by standard methods (2).
RESULTS
SHP represses HNF-4-mediated transactivation. Based on
both the association of SHP with a variety of nuclear hormone
receptors and the expression of SHP in liver, we tested the
capability of SHP to interact with the liver enriched orphan
receptor HNF-4 (38) in the yeast two-hybrid system. In this
assay, strong association was observed between a LexA-SHP
fusion and a B42-HNF4 fusion (W. Seol, unpublished obser-
vation). In order to further test the effect of SHP on HNF-4-
mediated transactivation, a reporter (12) containing a homopoly-
mer of five HNF-4 binding sites from the apolipoprotein B
promoter attached to a CAT reporter [(BA1)5CAT] was co-
transfected into HepG2 cells with SHP and HNF-4 expression
vectors. As shown in Fig. 1A, SHP inhibited HNF-4 transacti-
vation in a dose-dependent manner. This functional interac-
tion confirms the yeast results and indicates that HNF-4, like
many other nuclear receptors, is an inhibitory target of SHP
(17, 32–34).
Previous results have suggested that SHP inhibition may be
a reflection of inhibition of DNA binding (32). However, in
agreement with previous results with ER (34), no inhibitory
effect of SHP on HNF-4 DNA binding was observed (data not
shown). This result was not unexpected, since SHP targets the
putative LBD of HNF-4 in yeast, and this domain is not es-
sential for specific DNA binding by HNF-4 (16). To determine
whether SHP could inhibit transactivation by an HNF-4 LBD
tethered to DNA by a heterologous DNA binding domain, the
effect of SHP on an appropriate Gal4-HNF4 fusion was deter-
mined. As previously described (12), this Gal4-HNF4 fusion is
an apparently constitutive transactivator of a reporter contain-
ing Gal4 DNA binding sites. This constitutive activity was
specifically inhibited by SHP in a dose-dependent manner (Fig.
1B), indicating that SHP can directly inhibit transactivation
directed by the putative LBD of HNF-4. A direct role for the
SHP repression function in this inhibition is suggested by the
observation that, at the highest levels of SHP, expression was
reduced below the basal level observed with Gal4 alone.
SHP interacts with the AF-2 domain of HNF-4 in mamma-
lian cells. The association of SHP and HNF-4 previously indi-
cated by yeast two-hybrid results was confirmed by a two-
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hybrid approach in mammalian cells, using either a Gal4-SHP
fusion and a fusion of the VP16 transactivation domain to
HNF-4 or the reciprocal combination. As indicated in Fig. 2B,
coexpression of Gal4-SHP with the VP16-HNF4 fusion
strongly stimulated reporter gene expression from the re-
pressed state observed with Gal4-SHP alone. Coexpression of
VP16-SHP also increased reporter gene expression beyond
that observed with Gal4-HNF4 alone (Fig. 3B). To localize the
SHP sequences required for HNF-4 association, a previously
described series of SHP deletion mutants fused to Gal4 DNA
binding domain (33) (Fig. 2A) were cotransfected into HepG2
cells with VP16-HNF4. As observed with other SHP targets,
the constructs containing the SHP receptor association domain
(W160X, DN-148) showed a significant stimulation of lucif-
erase activity when coexpressed with VP16-HNF4, indicating
that this region is also sufficient for HNF-4 interaction (Fig.
2B). Importantly, and in strong contrast to previous results
with RXR (33), the loss of the SHP repression function in the
W160X fusion did not result in a significant increase in appar-
ent interaction. Previous results have demonstrated that the
loss of such repressor function potently increases reporter gene
expression in this system (33, 35). Thus, the lack of such an
increase indicates that the truncated W160X product interacts
more weakly with HNF-4 than the full-length SHP does. This
is consistent with results with RAR, ER, and other receptor
superfamily members (33, 34).
To identify HNF-4 sequences required for SHP interaction
in mammalian cells, a series of HNF-4 mutants fused to Gal4
(12) (Fig. 3A) was coexpressed with a VP16-SHP fusion in
HepG2 cells. Interestingly, a deletion of 6 amino acids remov-
ing the conserved AF-2 motif (Gal4-D2CD1b) essentially abol-
ished association with SHP, while an analogous construct with
an intact AF-2 motif (Gal4-D2CD1) showed a significant as-
sociation (Fig. 3B). Moreover, mutation of the conserved glu-
tamic acid (Glu363) at the core of the AF-2 motif (Gal4-
E363K) also blocked interaction with SHP. In contrast,
mutation of a leucine residue (Leu366) located just outside of
the conserved AF-2 motif (Gal4-L366E) did not impair SHP
association. These mammalian two-hybrid results were con-
firmed and extended by biochemical results demonstrating spe-
cific binding of 35S-labeled HNF4D2CD1 to a GST-SHP fusion
(Fig. 3C). As expected, binding was lost with the two HNF4
mutants affecting the AF-2 motif but retained with the L366E
mutant.
Overall, these results demonstrate that SHP requires the
HNF-4 AF-2 motif for interaction with HNF-4. This is in good
agreement with recent, independently derived results indicat-
ing that SHP targets the AF-2 surface of ER (17).
SHP competes with the coactivator SRC-3 for binding to
HNF-4. Two members of the p160 family, SRC-1 and SRC-2
(also known as TIF2 and GRIP-1) have been identified as
coactivators for HNF-4 (44). The third member of this family,
SRC-3 (also known as ACTR, AIB1, p/CIP, TRAM-1, and
RAC3) was also tested for stimulation of HNF-4 transactiva-
tion. An SRC-3 expression vector was introduced into HepG2
cells along with an HNF-4 vector and the (BA1)5CAT re-
porter. As expected, SRC-3 coexpression further stimulated
HNF-4 transactivation in a dose-dependent manner (data not
shown). To confirm that the conserved AF-2 motif of HNF-4 is
required for this SRC-3 stimulation, various deletion and point
mutants of HNF-4 fused to Gal4 were cotransfected into
HepG2 cells with the SRC-3 expression vector (Fig. 4). Gal4-
HFN4 D2CD1, which contains an intact AF-2 motif, showed
stimulation, but Gal4-HFN4 D2CD1b, which is missing this
motif, did not. Mutation of the conserved glutamic acid in the
AF-2 motif (E363K) decreased transactivation but, as previ-
ously observed with an analogous RXR mutant (42), did not
prevent SRC-3 stimulation. Thus, these results indicate that
the HNF-4 AF-2 motif is required for functional effects of
SRC-3.
Together, the results with SHP and SRC-3 suggest that these
two proteins should compete for the binding to the AF-2 sur-
face of HNF-4. To test this, the effect of SHP on the interac-
tion of SRC-3 and HNF-4 was examined in mammalian cells by
a two-hybrid competition assay. A Gal4 fusion of the receptor-
interacting domain of SRC-3 (amino acids 601 to 761) was
generated and transfected into HepG2 cells with a VP16-
HNF4 fusion. As expected, coexpression of these fusions re-
sulted in increased luciferase expression, reflecting an effective
SRC-3–HNF-4 interaction. As potential competitors, increas-
FIG. 1. Repression of HNF-4-mediated transactivation by SHP. (A) Repres-
sion of direct HNF-4 transactivation. HepG2 cells were cotransfected with 3 mg
of (BA1)5CAT, 50 ng of HNF-4, 0.75 mg of CMVb-Gal, and 50 ng to 1 mg of SHP
plasmid. At 40 h posttransfection, the cells were harvested for CAT and b-ga-
lactosidase assay. The CAT values are the means of normalized three indepen-
dent transfection experiments, each carried out in duplicate. (B) Repression of
Gal4-HNF4 transactivation. HepG2 cells were cotransfected with 25 ng of Gal4-
HNF4D2CD1 (Fig. 3A), 200 ng of TKGH, 200 ng of Gal4Tkluc reporter plas-
mid, and increasing amounts of SHP expression vector. CDM8 was used to
maintain a constant amount of receptor expression vector, and total DNA was
transfected. Cell extracts were prepared 48 h following transfection. Luciferase
activities normalized with GH values are plotted as the mean 6 standard devi-
ation (n 5 3).
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ing amounts of either VP16-SHP or VP16-SHPW160X were
added. (The VP16 activation domain was added to alleviate
concerns related to secondary effects of recruiting an inhibitory
SHP protein to an HNF-4–coactivator complex and to allow
detection of potential interaction of SHP with SRC-3. How-
ever, similar results were observed with SHP and SHP W160X
alone.) As indicated in Fig. 5, both competitors decreased the
interaction of SRC-3 with HNF-4. Consistent with the appar-
ently decreased affinity of the truncated mutant for HNF-4 as
noted above, VP16-SHPW160X was an approximately 10-fold-
weaker competitor than VP16-SHP. Since neither competitor
showed any apparent interaction with Gal4-SRC3 and the total
amount of VP16 expression vector was kept constant, we con-
clude that this decreased expression in this mammalian two-
hybrid system is a result of competition between SRC-3 and
SHP for binding to the AF-2 surface of HNF-4.
SHP competes with coactivators to bind RXR. The ability of
SHP to compete for coactivator binding to HNF-4 and the
suggestion of a similar mechanism for ER (17) raise the ques-
tion of the generality of this mechanism and also of its rela-
tionship to previously proposed direct activity of SHP as a
transcriptional repressor. These issues were addressed by using
RXR, which was previously shown to have a strong interaction
with SHP (33). As with HNF-4, the potential involvement of
the RXR AF-2 motif in the interaction with SHP was exam-
ined by the mammalian two-hybrid assay (Fig. 6A). Derivatives
of the LBD of wild-type RXR and a mutant lacking the C-
terminal AF-2 motif but capable of ligand binding (21, 52)
were constructed and tested for interaction with GAL-SHP. As
previously described, the full-length RXR exhibited a strong,
FIG. 2. HNF-4 interacts with the receptor interaction domain of SHP. (A)
Previously described SHP mutants (33) are diagrammed, fused to Gal4. INT and
REP represent receptor interaction and direct repression domains, respectively.
(B) SHP sequences required for SHP interaction in the mammalian two-hybrid
assay. Fifty nanograms of each of the deletion versions of murine SHP fused to
the Gal4 DNA binding domain was cotransfected into HepG2 cells with 50 ng of
a vector expressing VP16 alone or VP16-HNF4D2. Normalized luciferase ex-
pression directed by the Gal4Tkluc reporter is indicated as the mean 6 standard
deviation (n 5 3). WT, wild type.
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ligand-dependent interaction with full-length SHP. However,
SHP failed to bind the RXR lacking the AF-2 motif, indicating
that SHP also targets the activation surface of RXR. This was
confirmed by biochemical results demonstrating ligand-depen-
dent interaction of 35S-labeled wild-type RXR, but not the
RXR AF-2 mutant, with GST-SHP (Fig. 6B).
Since SRC-3 binds the same surface of RXR (6), the mam-
malian two-hybrid competition assay was used to determine
whether SHP also competes with coactivators for binding to
RXR in the presence of either 9-cis-RA or the synthetic RXR
agonist LG1069. Increasing concentrations of SHP efficiently
competed with SRC-3 for RXR binding (Fig. 7). In contrast to
the results with HNF-4, however, the ability of the SHPW160X
to compete was indistinguishable from that of full-length SHP.
This is consistent with previous results demonstrating that the
ability of this truncated SHP to interact with RXR is equivalent
to that of wild-type SHP (33).
Two-step repression by SHP. The efficient RXR interaction
of this mutant, which lacks the direct repression activity of
SHP, allowed a direct test of the relative importance of this
activity and coactivator competition in RXR inhibition. As
indicated in Fig. 8A, wild-type SHP efficiently repressed 9-cis-
RA-dependent transactivation by Gal4-RXR, even at rela-
tively low ratios of Gal4 and SHP expression vectors. However,
the effect of W160X was significantly weaker. As expected
from previous results with various Gal-SHP fusions (33), the
wild-type and truncated SHP proteins were expressed at equiv-
alent levels (data not shown). Thus, under circumstances
FIG. 3. SHP interacts with the AF-2 surface of HNF-4. (A) Gal4-HNF4
constructs used in mammalian two-hybrid mapping are diagrammed. (B) HNF-4
sequences required for SHP interaction in the mammalian two-hybrid assay.
Gal4 fusions (50 ng each) to the deletion or point mutant versions of HNF-4
were cotransfected with 50 ng of VP16 or VP16-SHP into HepG2 cells. Normal-
ized luciferase expression from the Gal4Tkluc reporter is shown. (C) The AF-2
surface of HNF-4 is required for interaction with SHP in vitro. GST alone or a
GST-SHP fusion protein were expressed in E. coli, bound to glutathione agarose,
and incubated with the indicated Gal4-HNF4 fusion proteins, which were 35S
labeled by in vitro translation. Specifically bound proteins were eluted by stan-
dard procedures (2) and are compared to 20% of the total input (bottom gel).
WT, wild type.
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where effects on DNA binding are excluded and the possible
involvement of any other receptors are minimized, the SHP
repression function is clearly required for full inhibition.
As noted above, the potential importance of the SHP re-
pression function was suggested by the effects of higher levels
of SHP on Gal4-HNF4 (Fig. 1B). This was examined in more
detail in the context of Gal4-RXR by a comparison of the
effects of higher levels of wild-type SHP and SHP W160X. As
demonstrated in Fig. 8B, the wild-type SHP decreased expres-
sion to levels well below the basal level observed with Gal4-
RXR in the absence of ligand and SHP, but the repression-
defective mutant failed to do so.
The importance of the SHP repression function was also
examined in the context of native RXR. RXR transactivation
of a reporter carrying the hormone response element from
CRBPII, which is efficiently activated by RXR homodimers
(25) (Fig. 8C), was decreased by both SHP and SHP W160X.
As expected, however, the wild-type SHP was a much more
effective inhibitor. In conclusion, while the SHP fragment ca-
pable of efficient coactivator competition in the previous re-
sults does show some inhibitory effects, they are much less than
those observed with the full-length SHP. Full inhibition by
SHP clearly requires its direct repressor activity, and at least
for RXR, this activity appears to be responsible for the major-
ity of the observed inhibition.
DISCUSSION
Previous results have demonstrated that the unusual orphan
receptor SHP inhibits transactivation by many different mem-
bers of the nuclear receptor superfamily. This was initially
attributed to inhibition of DNA binding (32). However, SHP
can also inhibit transactivation by targets that do not show such
DNA binding effects, including the estrogen receptor (34), the
Gal4 fusions described here, and at least a subset of the nu-
clear receptors that bind DNA as monomers (Y.-K. Lee, un-
FIG. 4. Stimulation of Gal4-HNF4 transactivation by SRC-3. Deletion or
point mutant versions of HNF-4 (Fig. 3) fused to the Gal4 DNA binding domain
(25 ng) were cotransfected into HepG2 cells with 500 ng of SRC-3. At 48 h after
transfection, cells were harvested for luciferase and GH assays. Normalized
luciferase expression directed by the Gal4Tkluc reporter is indicated as the
mean 6 standard deviation (n 5 3). WT, wild type.
FIG. 5. SHP competes specifically with SRC-3 for binding to HNF-4 in a
mammalian two-hybrid assay. HepG2 cells were cotransfected with 50 ng (each)
of Gal4SRC-3(RID), VP16 or VP16-HNF4, and the indicated amounts of VP16-
SHP and VP16-SHPW160X. Normalized luciferase expression directed by the
Gal4Tkluc reporter is indicated as the mean 6 standard deviation (n 5 3). The
decreased luciferase expression in the presence of increasing amounts of the
SHP proteins reflects decreased interaction between SRC-3 and HNF-4. Essen-
tially identical results were observed with intact SHP.
FIG. 6. SHP interacts with the AF-2 surface of RXR. (A) Mammalian two-
hybrid assay for interaction. Gal4SHP was transfected into HepG2 cells along
with VP16RXR, VP16RXRD19C, or VP16 alone. Approximately 20 h after
transfection, the cells were treated with 1 mM 9-cis-RA for 30 h. Normalized
luciferase expression directed by the Gal4Tkluc reporter is indicated as the
mean 6 standard deviation (n 5 3). (B) The AF-2 surface of RXR is required
for interaction with SHP in vitro. GST alone or a GST-SHP fusion protein were
expressed in E. coli, bound to glutathione agarose, and incubated with wild-type
RXR or the C-terminal D19 deletion mutant, both of which were 35S labeled by
in vitro translation. Specifically bound proteins were eluted by standard proce-
dures (2) and are compared to 20% of the total input (bottom gel).
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published observations). Two additional mechanisms have
been suggested to account for such inhibitory effects. The first
is based on the actions of the previously described direct tran-
scriptional repression function of SHP (33). In this case, re-
cruitment of the active repressor function of SHP to DNA via
interaction with another receptor would account for the de-
creased expression. The second is based on the competition
between SHP and coactivators for binding to an activated
receptor. This model, which was initially independently sug-
gested based on biochemical results demonstrating the ability
of SHP to inhibit coactivator binding to ER (17), is confirmed
and significantly extended by the results described here.
Importantly, these two mechanisms are not mutually exclu-
sive. This suggests a two-step model for SHP repression, at
least in cases where it does not affect DNA binding. In the first
step, SHP binding reduces expression by decreasing coactiva-
tor binding to an activated receptor. In the second, the direct
actions of SHP as a transcriptional repressor cause a further
decrease in expression. This two-step model is diagrammed in
Fig. 9.
It is interesting that a very similar two-step repression model
has also been suggested for SMAD-mediated transactivation.
In this case, the factor TGIF was suggested to displace coac-
tivators bound to SMADs and also to function directly as a
corepressor by recruiting histone deacetylase activity (45). As
previously described, SHP does not appear to interact with the
nuclear receptor corepressor NCoR (33), and preliminary re-
sults indicate that SHP repression is not affected by trichostatin
FIG. 7. SHP competes specifically with SRC-3 for binding to activated RXR
in a mammalian two-hybrid assay. HepG2 cells were cotransfected with 50 ng
(each) of Gal4-SRC3, VP16 or a VP16 fusion to the RXR LBD [VP16-RXR(L)],
and the indicated amounts of plasmids expressing VP16-SHP and VP16-
SHPW160X. 9-cis-RA (1 mM) was added 20 h after transfection, and cells were
further incubated for 30 h before harvest. Normalized luciferase expression is
plotted as the mean 6 standard deviation from three independent experiments.
Essentially identical results were obtained in treatments with the specific RXR
agonist LG1069. WT, wild type.
FIG. 8. SHP requires the repression domain for full inhibition. (A) A Gal4-
RXR(L) vector (50 ng) was cotransfected into HepG2 cells along with an SHP
or SHPW160X vector in the indicated ratio (Gal:SHP). At 20 h posttransfection,
cells were treated with 1 mM 9-cis-RA or vehicle alone and incubated for 30 h.
Normalized luciferase expression is plotted as the mean fold activation by 9-cis-
RA 6 standard deviation from three independent experiments. (B) Gal4-
RXR(L) vector (25 ng) was cotransfected into HepG2 cells with 200 and 800 ng
of SHP or SHPW160X expression vector as indicated by concentration ratio
(Gal:SHP). Normalized luciferase activities are plotted as percent activation or
repression. Percent activation for each combination is relative to the activation
observed with Gal4-RXR(L) in the presence of 9-cis-RA and the absence of
SHP. Percent repression is relative to basal expression for each combination in
the absence of 9-cis-RA. In this experiment, 800 ng of SHP or SHPW160X did
not affect luciferase expression in the presence of Gal4 alone. (C) A thymidine
kinase luciferase reporter containing the RXR response element from the CRB-
PII promoter was cotransfected into HepG2 cells with 50 ng of CDMhRXRa
and either the wild-type SHP or the SHPW160X expression vector in the indi-
cated ratio (RXR:SHP). Normalized luciferase expression was determined in
three independent experiments, and the fold response to 1 mM LG1069 is shown.
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A, a potent inhibitor of histone deacetylase activity. Thus, the
mechanism of the inhibitory effect of SHP remains unclear.
Nonetheless, the parallels in the actions of SHP and TGIF
emphasize the importance of mechanisms that function to rein
in the effects of a variety of activating signals and also suggest
that such two-step inhibition may be a general mechanism.
The existence of these two distinct steps for repression raises
the question of their relative contribution to the observed
inhibitory effects. The results described here demonstrate that
the loss of the SHP repression function leads to a loss of the
majority of the inhibition. Thus, at least for RXR, the direct
activity of SHP as a transcriptional repressor is apparently
responsible for the majority of the inhibitory effect. It is cer-
tainly possible that this activity could be less effective with
other receptors or in other cell types. However, the apparent
importance of this repressor function is consistent with genetic
results with DAX-1, the only nuclear receptor superfamily
member that is similar to SHP (50). These two orphans both
lack a conventional DNA binding domain and also share a
repression function that appears to be based on conserved
C-terminal sequences (15, 19, 33). Surveys indicate that this
C-terminal region is affected by all of the more than 40 muta-
tions of the human DAX-1 gene identified in patients with
congenital adrenal hypoplasia, including 7 single amino acid
substitutions (19, 53). The striking prediction that all of these
mutations affect repressor function has been supported by
more recent results (e.g., reference 31). This clearly supports
the importance of this function for DAX-1.
The results described here also add HNF-4 to the list of SHP
targets. The potential importance of the functional interaction
between these two orphans is supported by their coexpression
in liver and pancreatic beta cells. This is reinforced by the fact
that only a minor perturbation of HNF-4 activity results in the
syndrome of mature-onset diabetes of the young (48), suggest-
ing that the modulation of HNF-4 activity by SHP could have
important metabolic effects. A determination of the conse-
quences of the loss of SHP function will be required to assess
the significance of this and other potential roles for SHP.
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